INFLAMMATORY BOWEL DISEASE: Edited by Claudio FiocchiComplications of biologics in inflammatory bowel diseaseSousa, Paula; Allez, MatthieuAuthor Information Department of Gastroenterology, Hôpital Saint Louis APHP, Paris, France Correspondence to Matthieu Allez, MD PhD, Department of Gastroenterology, Hôpital Saint-Louis APHP, 1 Avenue Claude Vellefaux, 75010 Paris, France. Tel: +33 142 49 95 97; fax +33 142 49 91 68; e-mail: [email protected] Current Opinion in Gastroenterology: July 2015 - Volume 31 - Issue 4 - p 296-302 doi: 10.1097/MOG.0000000000000191 Buy Metrics Abstract Purpose of review The treatment of inflammatory bowel disease (IBD) in the modern area has improved with more biological agents available. Although the efficacy of these drugs has been demonstrated, concerns about their safety profile have been raised, and new data have emerged in the past year. Recent findings New data regarding the safety profile of anti-TNF were published over the last year, with a better identification of patients at risk of infection, and specific recommendations for the prevention of infections. There is a mild increase in malignancy in patients receiving anti-TNF, mainly lymphoma and skin cancer, which seems mainly attributable to combination with thiopurines. Specific recommendations for management of pregnancy were published. Summary Biological treatments are effective and safe in the treatment of IBD, provided that the recommendations for their use and monitoring are followed. Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.